ABSTRACT

INTRODUCTION: Pulpotomy of carious primary teeth with an exposed pulp is a common treatment option. Pulpotomy has been conducted with various medicaments over the years. The aim of this study was to evaluate clinical and radiographic success of primary vital pulpotomy with ProRoot and Root MTA.

MATERIALS AND METHODS: In this randomized clinical trial, children aged between 3-7 years who met the inclusion criteria were enrolled. A total of 70 teeth were deemed suitable under the inclusion criteria and teeth were randomly divided into the 2 groups; ProRoot and Root MTA. Pulpotomy was performed and immediately followed by coronal amalgam restoration. The clinical and radiographic follow ups were conducted 6, 12, 18, 30 months post-operatively. The data were analyzed using Exact Fisher test.

RESULTS: At the final follow up, 28 teeth in ProRoot MTA and 26 teeth in Root MTA were evaluated. In the Root MTA group, 1 tooth had exfoliated and one had an abscess and furcal radiolucency radiographically. In ProRoot MTA group, external resorption was observed in 1 tooth. Statistical analysis did not show significant difference in success rate between 2 groups after 30 months.

CONCLUSION: The success rates of Root and ProRoot MTA are similar, indicating that pulpotomy can be carried out successfully in both primary molars.
Table 1. Radiographic signs 30 months after pulpotomy with Root MTA and ProRoot MTA

| Materials    | N | IR\(^a\) | ER\(^b\) | FR\(^c\) |
|--------------|---|---------|---------|---------|
| Root MTA     | 26 | 0       | 0       | 1 (3.8%) |
| ProRoot MTA  | 28 | 0       | 1 (3.5%)| 0       |

\(a\). IR: Internal resorption, \(b\). ER: External resorption, \(c\). FR: Furcal radiolucency

Results of a further clinical study revealed that the difference in success rate of pulpotomy with Root MTA, ProRoot MTA after 12 months is not statistically significant (22). The aim of this study was to compare the long term clinical and radiographic success rate of pulpotomy with Root MTA and ProRoot MTA.

MATERIALS AND METHODS

This randomized clinical trial was performed on children who were referred to pediatric department of Shahed Dental School for dental treatment. Inclusion criteria for subjects were 1) age range of 3-7 years; 2) primary molar in need of pulpotomy; 3) healthy systemic status with no contraindication for pulpotomy; 4) carious primary molar teeth that required pulpotomy. Written informed consent was obtained from their parents. The clinical criteria for tooth selection were 1) no clinical symptoms such as spontaneous pain during the night; 2) no tenderness to pressure/percussion; 3) no mobility; 4) absence of associated swelling or sinus tract; 5) absence of vital carious pulp exposure on examination; and 6) presence of restorable crowns. Radiographic criteria included the absence of: 1) internal and external resorption; 2) furcal radiolucency; and 3) root canal calcifications. Seventy teeth, in accordance with similar studies (6,15,22), that met the inclusion criteria were randomly allocated in either Root MTA (Tabriz, Iran) or ProRoot MTA (DENTSPLY Tulsa), (ProRoot group code 0, Root MTA group code 1). Randomized allocation was conducted by dental assistant who was blinded to the study design. The primary tooth pulpotomies were performed by the same pedodontist throughout the study. After anesthesia, caries was removed and coronal access was made with a #245 bur (Dentsply Maillefer, Tulsa, OK, USA) and high speed hand piece. Coronal pulp was removed with a spoon excavator; subsequently, the pulp chamber was irrigated with saline. Hemorrhage was controlled by placing a cotton pellet moistened in saline with slight pressure. Once hemostasis was achieved in both groups the material were mixed according to instructions and placed within the pulp chamber. All teeth were restored with amalgam and examined after 6, 12, 18 and 30 months clinically and radiographically by a blind dentist. Clinical and radiographic success criteria were as follows: 1) the absence of pain, mobility, swelling, and sinus tract; and 2) radiographic absence of internal and external resorption and furcal radiolucency (23-25). The presence of even single clinical and/or radiographic failure rendered the treatment as a failure. Data were analyzed using Fisher Exact test.

RESULTS

At the 6 month post-operative evaluation, 34 teeth in Root MTA group and 33 teeth in ProRoot MTA group were examined. No failure was observed in the 6-month samples. In the 12 months follow up, 31 teeth in ProRoot and 31 teeth in Root MTA group were evaluated. In Root MTA group, all the cases showed successful results. In ProRoot MTA group, two failures were observed including an abscess and furcal radiolucency. Fisher Exact test revealed no statistically difference in success rate between ProRoot and Root MTA. The 18-month follow up was performed on 30 cases in ProRoot MTA and 31 cases in Root MTA group which were all successful. During the 30 months post operative evaluation, 28 teeth in ProRoot MTA and 26 teeth in Root MTA groups were available for assessment. In the Root MTA group, one tooth exfoliated and one demonstrated abscess and furcal radiolucency (as well as canal calcification which impeded pulpectomy treatment) at the 30 month follow up evaluation (Table 1 and Table 2). In ProRoot MTA external resorption was seen in 1 tooth; the difference between two groups was not statistically significant.

DISCUSSION

Pulpotomy is a common treatment modality in primary teeth with carious exposed pulp. This procedure preserves the tooth and the arch space for permanent teeth; thereby avoiding future problems (26,27). Formocresol is the common medicament in pulpotomy; it has some distinct disadvantages such as cytotoxicity and potential
Table 2. Clinical signs 30 months after pulpotomy with Root MTA and ProRoot

| Clinical signs     | Pain | Swelling | Mobility | Sinus tract | Tenderness to percussion | Abscess |
|--------------------|------|----------|----------|-------------|--------------------------|---------|
| Root MTA(26)       | 0    | 0        | 0        | 0           | 0                        | 1(3.8%) |
| ProRoot MTA(28)    | 0    | 0        | 0        | 0           | 0                        | 0       |

of mutagenicity and carcinogenicity. (28,29). MTA is biocompatible and antibacterial material with little cytotoxicity. Moreover, it induces cell proliferation and regeneration (3-5,8-9), and has been proposed as a suitable medicament for pulpotomy. Root MTA has been produced in Iran and has the same favorable characteristics of ProRoot MTA (20-22). In this study, we evaluated the long-term success rate of pulpotomy of primary molars with Root MTA and ProRoot MTA. Results of this study showed high radiographic (Root MTA=96.16% and ProRoot MTA=100%) and clinical (Root MTA=96.16% ProRoot MTA=96.43%) success. The difference between two materials was not statistically significant.

Ramezankhani et al. and Sadre Lahigani's et al. demonstrated that the inflammation and biocompatibility of ProRoot MTA and Root MTA was not different, possibly due to their similar characteristics and composition (21,30). A previous study reported 100% clinical and radiographic success rates for pulpotomy with Root MTA and 96.78% success rates for pulpotomy with ProRoot MTA after 1 year, concurring with our study (22); however, our study consisted of longer follow up period.

Only one tooth demonstrated periapical infection and root canal calcification impeding further treatment in the present study. This may only pose a problem to treatment outcome if a significant percentage of pulpotomized primary teeth demonstrated root calcifications and associated abscesses following treatment. In this study, clinical and radiographic success rate of ProRoot and Root MTA was favorable after 30months.

CONCLUSION

ProRoot MTA and Root MTA can be considered suitable materials for pulpotomy of primary molars. Further studies should address and compare the histological success rates of ProRoot and Root MTA.

ACKNOWLEDGMENT

We would like to thank Mr. Naser Vallaii for his assistance in statistical analysis.

Conflict of Interest: ‘None declared’.

REFERENCES

1. Nadin G, Goel BR, Yeung CA, Glenny AM. Pulp treatment for extensive decay in primary teeth. Cochrane Database Syst Rev 2003;1:CD003220.
2. Fuks AB. Current concepts in vital primary pulp therapy. Eur J Paediatr Dent 2002;3:115-20.
3. Shumayrikh NM, Adenubi JO. Clinical evaluation of glutaraldehyde with calcium hydroxide and glutaraldehyde with zinc oxide eugenol in pulpotomy of primary molars. Endod Dent Traumatol 1999;15:259-64.
4. Haghgoo R, Jalali Nadoshan MR. Histopathological evaluation of pulp changes after ferric sulfate and formocresol pulpotomy in primary teeth. J of Islamic Dental Association of IRAN 2007;18:70-5.
5. Fadavi S, Anderson AW. A comparison of the pulpal response to freeze-dried bone, calcium hydroxide, and zinc oxide-eugenol in primary teeth in two cynomolgus monkeys. Pediatr Dent 1996;18:52-6.
6. Bahrololumi Z, Emtyazi M, Hoseini G: Clinical and radiographic comparison of pulpotomized primary molars with formocresol and electrosurgery. Indian Journal of Dental Research 2008;19:219-23.
7. Maroto M, Barberia E, Vera V, Garcia-Godoy F. Dentin bridge formation after white mineral trioxide aggregate (white MTA) pulpotomies in primary molars. Am J Dent 2006;19:75-9.
8. Torabinejad M, Hong CU, McDonald F, Pitt Ford TR. Physical and chemical properties of a new root-end filling material. J Endod 1995;21:349-53.
9. Ingle J, Bakland, editors. Endodontics, 5th Edition. Bc Decker Co, 2002: pp.706.
10. Cohen S, Burn R, editors. Pathway of pulp, 8th Edition. Mosby Co, 2002: pp.721
11. Torabinejad M, Hong CU, Pitt Ford TR, Kettering JD. Antibacterial effects of some root end filling materials. J Endod 1995;21:403-6.
12. Fischer EJ, Arens DE, Miller CH. Bacterial leakage of mineral trioxide aggregate as compared with zinc-free amalgam, intermediate restorative material, and Super-EBA as a root-end filling.
13. Martell B, Chandler NP. Electrical and dye leakage comparison of three root-end restorative materials. Quintessence Int 2002;33:30-4.
14. Fallahinejad Ghajari M, Mirkarimi M, Vatanpour M, Kharrazi Fard MJ. Comparison of pulpotomy with formocresol and MTA in primary molars. Iranian Endod J 2008; 3:45-9.
15. Ansari G, Ranjpour M. Mineral trioxide aggregate and formocresol pulpotomy of primary teeth: a 2-year follow-up. Int Endod J 2010;43:413-8.
16. Noorollahian H. Comparison of mineral trioxide aggregate and formocresol as pulp medicaments for pulpotomies in primary molars. Br Dent J 2008;14:204.
17. Haghgoo R, Abbasi F. Clinical and radiographical success of pulpotomy with mineral trioxide aggregate with formocresol in primary molar. Dental Journal of Shaid Beheshti University of Medical Sciences 2008; 26: 340-5.
18. Farsi N, Alamoudi N, Balto K, Mushayt A. Success of mineral trioxide aggregate in pulpotomized primary molars. J Clin Pediatr Dent 2005;29:307-11.
19. Aeinehchi M, Dadvand S, Fayazi S, Bayat-Movahed S. Randomized controlled trial of mineral trioxide aggregate and formocresol for pulpotomy in primary molar teeth. Int Endod J 2007;40:261-7.
20. Behforozi E, Ghoddosi J, Tavakkoli J. Evaluation of cytotoxic effect of amalgam, Root MTA in culture environment of cellular line of HGF fibroblasts [thesis]. Dental school, Mashhad University of Medical Sciences, 2002.
21. Ramezankhani N, Razmi H. Histological evaluation of tissue response to Root MTA, MTA, Portland cement implanted in mandible of mature cat[thesis]. Dental School, Tehran University of Medical sciences 2003.
22. Haghgoo R, Jalayer T. Evaluation of clinical and radiographic success of Iranian and original mineral trioxide aggregate(MTA) in primary molars pulpotomy J of Islamic Dental Association of IRAN 2008; 20: 60-4.
23. McDonald RE, Avery DR, Dean JA. Treatment of deep caries vital pulp exposure and pulpless teeth. In: McDonald RE, Avery DR, Dean JA, editors. Dentistry for the child and adolescent. 8th Edition. St.Louis: CV Mosby, 2004: pp. 390.
24. Camp JH, Fuks AB: Endodontic treatment for the primary and young permanent dentition. In: Cohen S, Hargreaves KM, editors. Pathways of the pulp, 9th Edition. St. Louis: Mosby Elsevier; 2006: pp. 834-59.
25. Fuks AB. Pulp therapy for the primary dentition. In: Pinkham JR, Casamassimo PS, Fields jr HW, editors. Pediatric Dentistry infancy through adolescence, 4th Edition. Elsevier Saunders, 2005: pp. 379-80.
26. Strange DM, Seale NS, Nunn ME, Strange M. Outcome of formocresol/ZOE sub-base pulpotomies utilizing alternative radiographic success criteria. Pediatr Dent 2001; 23:331-6.
27. American Academy of Pediatric Dentistry. Guideline on pulp therapy for primary and young permanent teeth. Pediatr Dent 2004;26:115-9.
28. Nunn JH, Smeaton I, Gilroy J. The development of formocresol as a medicament for primary molar pulpotomy procedures. ASDC J Dent Child 1996;63:51-3.
29. Zarzar PA, Rosenblatt A, Takahashi CS, Takeuchi PL, Costa Júnior LA. Formocresol mutagenicity following primary tooth pulp therapy: an in vivo study. J Dent 2003;31:479-85.
30. Sadr Lahijani M, Abedini R, Khaksari M, Shojaiifar H, Shadkam Farrokhi A, Raof Kateb HR. Comparison of tissue response to Original MTA (ProRoot) and Iranian MTA (Root) in rat. Journal of Dental School, Shahid Beheshti University of Medical Sciences 2006;23:80-7.